Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, ...
Earlier in December 2025, BofA Securities upgraded Schrödinger, Inc. after the company shifted away from internal drug development to concentrate on its core computational software business. This ...
Recent upgrades from BofA Securities and KeyBanc have put fresh attention on Schrödinger (SDGR), as the company moves away from expensive in-house drug development and focuses more on its higher ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...
Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world.
Schrödinger to receive $55 million upfront; eligible to receive up to $2.7 billion in milestone payments plus royalties NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results ...
Collaboration Enables Pharma Industry Giants, Biotech Startups to Use Schrödinger’s Computational Drug Discovery Platform Boosted by NVIDIA DGX SuperPOD and NVIDIA Clara Discovery Libraries SANTA ...
Schrödinger to receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties Expanded multi-year software agreement enables technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results